Studienregister

NeuroID

Psychoonkologische Wirksamkeit einer EEG Neurofeedback-Intervention bei Menschen mit malignem Melanom

Berufsordnung (BO) / Interventionell

Im Rahmen dieser Studie wurden psychoonkologische Patient*innen nach einer fünfwöchigen Warteliste randomisiert einer von zwei Interventionsbedingungen (Neurofeedback vs. Achtsamkeit) zugeteilt. Fragebogenerhebungen sowie EEG-Untersuchungen wurden vor der Warteliste, vor und nach der fünfwöchigen Intervention, sowie bei einem Follow-Up nach weiteren fünf Wochen durchgeführt.

ENCORAFENIB t BINIMETINIB

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria

Berufsordnung (BO) / Nicht-interventionell

IRINA

Influence of timing of Radiotherapy on Immune respoNse to checkpoint blocker treatment in patients with metastasized melanomA

Berufsordnung (BO) / Nicht-interventionell

Field_Cancerization

Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced field cancerization. An open label, prospective, observational biomarker study of the DeCOG

Arzneimittelgesetz (AMG) / Phase 4, Interventionell, Multizentrisch

A study to investigate the clinical and immunological effects on field cancerization in patients treated with PD-1 inhibition for advanced or metastatic cutaneous squamous cell carcinoma

EudraCT-Nummer: 2021-006372-17

CA224-127

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresecable Melanoma

Arzneimittelgesetz (AMG) / Phase 3, Interventionell, Multizentrisch

EudraCT-Nummer: 2022-000575-39

NCT-Nummer: NCT05625399

R3767-ONC-2055

A Phase 3 Trial of Fianlimab (Anti-Lag-3) and Cemiplimab versus Pembrolizumab in the adjuvant setting in patients with completely resected High-Risk-Melanoma

Clinical Trial Regulation (CTR) / Interventionell

NCT-Nummer: NCT05608291

IMCgp100-203

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Arzneimittelgesetz (AMG) / Phase 2, Interventionell, Multizentrisch

EudraCT-Nummer: 2022-502732-39-00

NCT-Nummer: NCT05549297

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Arzneimittelgesetz (AMG) / Phase 1, Interventionell, Multizentrisch

PH-L19IL2TNFNMSC-04/19

A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions.

Arzneimittelgesetz (AMG) / Phase 2, Interventionell, Multizentrisch

Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients

EudraCT-Nummer: 2020-003299-42

NCT-Nummer: NCT04362722

ARCHITECT

Non-Interventionelle ADOREG Registerstudie zur Charakterisierung einer Kombination aus Immuntherapie und Elektrochemotherapie beim malignen Melanom

Berufsordnung (BO) / Nicht-interventionell

IOB-032/PN-E40

Phase II, multi-cohort trial of neoadjuvant and post-surgery IO102-IO103 and pembrolizumab in patients with selected resectable tumors

Arzneimittelgesetz (AMG) / Phase 2, Interventionell, Multizentrisch

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

NCT-Nummer: NCT05280314

V940-001

Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma

Arzneimittelgesetz (AMG) / Phase 3, Interventionell

MK4280A-010

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Cofrimulation of Favezelimab (MK-4280) with Pembrolizumab (MK3475) in Selected Solid Tumors

Arzneimittelgesetz (AMG) / Interventionell, Multizentrisch

GSK 219538

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Target Engement of GSK1070806 SC injection in participants with Moderate to Severe Atopic Dermatitis

Arzneimittelgesetz (AMG) / Phase 2, Interventionell

IFX-1-P3.4

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum.

Arzneimittelgesetz (AMG) / Phase 3, Interventionell, Multizentrisch

NCT-Nummer: NCT05964413

DICIT

Efficacy of diclofenac added to ongoing PD-1 inhibitor therapy in metastatic melanoma patients

Arzneimittelgesetz (AMG) / Phase 2, Interventionell

Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients. A single arm phase II trial

Das Studienregister der UME

- Klinik für Dermatologie -

Aktuelle Studien

NeuroID

Psychoonkologische Wirksamkeit einer EEG Neurofeedback-Intervention bei Menschen mit malignem Melanom

ENCORAFENIB t BINIMETINIB

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria

IRINA

Influence of timing of Radiotherapy on Immune respoNse to checkpoint blocker treatment in patients with metastasized melanomA

Field_Cancerization

Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced field cancerization. An open label, prospective, observational biomarker study of the DeCOG

CA224-127

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresecable Melanoma

R3767-ONC-2055

A Phase 3 Trial of Fianlimab (Anti-Lag-3) and Cemiplimab versus Pembrolizumab in the adjuvant setting in patients with completely resected High-Risk-Melanoma

IMCgp100-203

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

PH-L19IL2TNFNMSC-04/19

A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions.

ARCHITECT

Non-Interventionelle ADOREG Registerstudie zur Charakterisierung einer Kombination aus Immuntherapie und Elektrochemotherapie beim malignen Melanom

IOB-032/PN-E40

Phase II, multi-cohort trial of neoadjuvant and post-surgery IO102-IO103 and pembrolizumab in patients with selected resectable tumors

V940-001

Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma

MK4280A-010

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Cofrimulation of Favezelimab (MK-4280) with Pembrolizumab (MK3475) in Selected Solid Tumors

GSK 219538

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Target Engement of GSK1070806 SC injection in participants with Moderate to Severe Atopic Dermatitis

IFX-1-P3.4

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum.

DICIT

Efficacy of diclofenac added to ongoing PD-1 inhibitor therapy in metastatic melanoma patients